Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).

Saved in:
Bibliographic Details
Title: Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).
Authors: Pascual T; SOLTI Cancer Research Group, Barcelona, Spain.; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain., Vidal M; SOLTI Cancer Research Group, Barcelona, Spain.; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.; Breast Cancer Unit, IOB-QuirónSalud, Barcelona, Spain., Cejalvo JM; SOLTI Cancer Research Group, Barcelona, Spain.; Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.; Biomedical Research Institute INCLIVA, Valencia, Spain., Vega E; Medical Oncology Department, Centro Integral Oncológico Clara Campal, Madrid, Spain., Sanfeliu E; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.; Pathology Department, Hospital Clínic de Barcelona, Barcelona, Spain., Villacampa G; SOLTI Cancer Research Group, Barcelona, Spain.; Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Ganau S; Radiology Department, Hospital Clínic de Barcelona, Barcelona, Spain., Parreño AMJ; Radiology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain., Zamora E; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Miranda I; Radiology Department, Chief of Breast Imaging Unit. International Breast Cancer Center (IBCC) and Centro Médico Teknon, Barcelona, Spain., Delgado A; Radiology Department, Centro Integral Oncológico Clara Campal, Madrid, Spain., Bermejo B; Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.; Biomedical Research Institute INCLIVA, Valencia, Spain.; Medicine Department, Universidad de Valencia, Valencia, Spain., Seguí E; SOLTI Cancer Research Group, Barcelona, Spain.; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Brasó-Maristanty F; SOLTI Cancer Research Group, Barcelona, Spain.; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.; Reveal Genomics, Barcelona, Spain., de la Cruz-Merino L; Cancer Immunotherapy, Biomedicine Institute of Seville (IBIS)/CSIC, Clinical Oncology Department, University Hospital Virgen Macarena and School of Medicine, University of Seville, Seville, Spain., Juan M; Immunology Department, Hospital Clínic de Barcelona, Barcelona, Spain., Galván P; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Gonzàlez-Farré X; SOLTI Cancer Research Group, Barcelona, Spain.; Institut Oncològic Dr. Rosell, Hospital Universitari General de Catalunya, Sant Cugat, Spain., Chillara S; SOLTI Cancer Research Group, Barcelona, Spain., Villagrasa P; Reveal Genomics, Barcelona, Spain., Pfefferle AD; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., O'Connell CE; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Ferrero-Cafiero JM; SOLTI Cancer Research Group, Barcelona, Spain., Oliveira M; SOLTI Cancer Research Group, Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Perou CM; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Prat A; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain. alprat@clinic.cat.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. alprat@clinic.cat.; Medicine Department, University of Barcelona, Barcelona, Spain. alprat@clinic.cat.; Breast Cancer Unit, IOB-QuirónSalud, Barcelona, Spain. alprat@clinic.cat.; Reveal Genomics, Barcelona, Spain. alprat@clinic.cat.
Source: Nature communications [Nat Commun] 2026 Feb 16; Vol. 17 (1). Date of Electronic Publication: 2026 Feb 16.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-1723
DOI:10.1038/s41467-026-69222-5